



Published in final edited form as:

*Adv Geriatr Med Res.* 2022 ; 4(1): . doi:10.20900/agmr20220003.

## Near-Lifespan Tracking of Cerebral Microvascular Degeneration in Aging to Alzheimer's Continuum

Jonghwan Lee<sup>1,2</sup>

<sup>1</sup>Center for Biomedical Engineering, School of Engineering, Brown University, Providence, RI 02912, USA

<sup>2</sup>Carney Institute for Brain Science, Brown University, Providence, RI 02912, USA

### Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions of people worldwide and is currently incurable. As the population ages, AD and related dementia are becoming the biggest epidemic in medical history: the number of people aged 65 and older with AD is projected to increase between two- and three-fold by 2050. Imaging and biomarker studies suggest that the pathophysiological processes of AD begin more than a decade before the diagnosis of dementia, opening the possibility of early, preemptive prediction. For accurate prediction, it is important although challenging to fully understand how multiple etiologies and age-related prodromal processes contribute to the onset of Alzheimer's continuum, across a long period comparable to the lifespan. Addressing this challenge was one of the overarching transformative concepts at the 2015 AD Research Summit, "to develop new programs on *systems biology and integrative physiology* to gain a deeper understanding of the complex biology of the disease."

Among other factors, cerebral microvascular degeneration (CMD) may play a key role in the onset and development of Alzheimer's continuum, potentially prior to, along with, or independently of the beta-amyloid (A $\beta$ ) accumulation. Despite its importance for early detection and as a therapeutic target for early intervention, it is unknown whether CMD is a causal factor for AD pathogenesis or an early consequence of multifactorial conditions that lead to AD at a later stage. Here, this *Viewpoint* suggests that we should fill two critical knowledge gaps: (1) Temporal relationships between various CMDs and other key factors before/during/after the onset of Alzheimer's continuum have not been established; (2) Little integrative study down to the capillary vessel level has been conducted on how individual defects in various microvascular structural and flow properties distinctly correlate with and/or contribute to neuronal degeneration. As the first step toward filling these gaps, I propose utilizing recent advances in microscopic imaging and image analysis techniques to longitudinally track a comprehensive set of CMDs over the lifespan in model animals, along with A $\beta$ , tau, neuronal degeneration, and cognitive impairment when possible.

---

This is an open access article distributed under the terms and conditions of Creative Commons Attribution 4.0 International License.  
jonghwan\_lee@brown.edu .

CONFLICTS OF INTEREST

The author declares to have no conflicts of interest.

## Keywords

Alzheimer's disease; vascular factor; microvascular degeneration; longitudinal tracking; integrative pathophysiology

---

## MICROVASCULAR DYSFUNCTION CAN CAUSE NEURONAL DEGENERATION

Neurons depend on blood vessels for oxygen and nutrients, as well as for removal of carbon dioxide and other potentially toxic metabolites. For normal functioning of neuronal circuits, cerebral blood flow (CBF) should be well maintained during the resting state and properly regulated in response to neural activation to meet the metabolic demand of neurons, location by location, moment by moment [1]. At the microvascular scale, cortical capillary blood vessels play an important role in this CBF supply and regulation [2], and thus in normal functioning of neuronal circuits.

Among various pathways by which a microvascular deficit causes neuronal degeneration, major players include hypoperfusion, dysregulated functional hyperemia, and reduced clearance [3] (See Ref. [4] for a comprehensive list of related vascular pathways). First, severe hypoperfusion leading to hypoxia causes an array of detrimental effects on neurons [5]; even mild hypoperfusion decreases protein synthesis in neurons and eventually leads to a cascade of neuronal loss [6]. Hypoperfusion also alters electrolyte balances and water gradients, leading to edema and white matter damage, and interestingly, facilitates the accumulation of A $\beta$  plaques [7–10]. At the microvascular scale, capillary vessel flow patterns are directly related to the extraction efficacy of oxygen in the brain parenchyma [11,12]; a deficit in the flow pattern like an increased heterogeneity may lead to neurodegeneration even in the absence of artery-level hypoperfusion [13]. Second, dysregulated functional hyperemia or neurovascular coupling is also believed to lead to or be associated with neuronal damage in many disorders, some of which may occur independently of the resting-state hypoperfusion [14,15]. Third, influx and efflux of interstitial fluid (ISF) and cerebrospinal fluid (CSF) affect brain transfer of intravascular substances. Dysfunction in two related pathways, the intramural peri-arterial drainage pathway of ISF and the glymphatic system pathway of CSF, may contribute to neuronal degeneration via ineffective waste clearance [16].

Blood-brain barrier (BBB), although not within the vascular system, also plays a key role in neuronal degeneration when it dysfunctions; thus, this *Viewpoint* includes BBB dysfunction to a broad definition of cerebral microvascular degeneration (CMD). BBB breakdown leads to leaking and/or formation of components toxic to neurons, including thrombin and reactive oxygen species [17,18], and results in hypoperfusion through albumin-promoted vasogenic edema [19].

## VARIOUS CEREBRAL MICROVASCULAR DEGENERATIONS ARE OBSERVED IN ALZHEIMER'S DISEASE

Hypoperfusion is observed near the onset of Alzheimer's continuum in patients and animal models. The degree of hypoperfusion differs by brain regions and measurement techniques, but many imaging studies consistently show significant hypoperfusion in the hippocampus and parietal and temporal cortices [20–30]. A population-based study found that cerebral hypoperfusion is associated with accelerated cognitive decline and an increased risk of dementia [31,32]. Studies using transgenic mice observed hypoperfusion even at young ages when there are no amyloid plaques [33], as well as a potent link between cerebral hypoperfusion and parenchymal A $\beta$  pathology [34]. At the microvascular scale, both structural defects and functional deficits are observed in AD, such as more string vessels, reduced capillary density, increased tortuosity, thickened and irregular basement membranes, increased BBB permeability, and increased capillary transit time heterogeneity [35–39]. A recent study using in-vivo two-photon fluorescence microscopy found that AD mice exhibit stalled blood flow in more cortical capillaries than wild-type mice [40].

In addition to these deficits in vascular structures and resting-state CBF, dysregulations in functional hyperemia or neurovascular coupling are observed in AD patients and animal models. Imaging studies revealed such dysregulations during memory-related tasks [41,42], verbal tasks [43,44], and in response to visual stimuli [45,46]. At the microvascular scale, early homogenization of capillary blood flow in response to functional activation, which we demonstrated in wild-type animals [47], is absent in 18-month-old AD mice [48].

These CMDs likely interact with A $\beta$  accumulation in a complicated manner, as A $\beta$  often deposits on the vessel wall, leading to vascular dysfunction, while the hypoperfusion accelerates A $\beta$  accumulation. And the BBB is an important player in these complicated interactions. For example, a magnetic resonance imaging study found that water exchange rate across the BBB is associated with cerebrospinal fluid (CSF) A $\beta$ <sub>42</sub> in healthy older adults [49]. This feed-forward interaction makes it particularly difficult to clarify the mechanistic roles of CMD in AD. But a human study published in 2020 reported a very interesting finding [50]. Carriers of APOE4, a major risk gene in sporadic AD, exhibited higher BBB breakdown in the hippocampus and medial temporal lobe when their cognitive impairment was either absent or very mild. More importantly, the observed BBB breakdown was independent of CSF levels of A $\beta$  and Tau. This independence suggests that early CMD may serve as an initial pathogenesis in Alzheimer's continuum separately from the A $\beta$  pathogenesis, although two factors may feed-forward each other in a later stage of the disease.

## TWO CRITICAL KNOWLEDGE GAPS REGARDING CMD IN ALZHEIMER'S CONTINUUM

Despite these increasing pieces of evidence, temporal relationships between CMD and other key factors in the onset and development of Alzheimer's continuum are not clear. This knowledge gap was pinpointed by a comprehensive review [3]: “The *time course* of these

vascular alterations and how they relate to dementia and Alzheimer's disease pathology remain unclear, as no protocol that allows the development of the diverse brain vascular pathology to be scored, and hence *to be tracked with ageing*, has so far been developed and widely validated." Since then, a multifactorial data-driven analysis led to a tentative temporal ordering of various factors in the progression of late-onset AD [51]. This study suggested that vascular alterations may occur earlier than the other factors, but these time courses have not been tracked in real experiments with aging.

Second, each of various CMDs will have a different degree of contribution to, or correlation with, neuronal degeneration. However, most prior research has investigated only a few structural defects or flow deficits at a time, making it difficult to compare the degrees of contribution quantitatively across different studies. A more rigorous approach will be to track and compare a comprehensive set of CMDs at once within the same subject (i.e., in a longitudinal manner). More importantly, few studies investigated CMDs in multiple scales at once, from pial vessels to individual capillaries.

## CONCLUSIONS

The major challenge in filling the knowledge gap is that Alzheimer's continuum develops very slowly and thus it is nearly impossible to longitudinally track CMD in humans for a long period comparable to a fraction of the lifespan. Such longitudinal tracking has been challenging even in model animals with much shorter lifespans. Here this *Viewpoint* suggests that recent advances in microscopic rodent brain imaging and image analysis techniques may enable it (see Ref. [52] for example), and the AD research community should utilize the advanced techniques in model animals to fill the critical knowledge gaps. Findings from such studies will provide unprecedented insight into the mechanistic roles of CMD in Alzheimer's continuum. They will in turn facilitate translational/clinical research for CMD-based early detection and treatment of the disease that is becoming the biggest epidemic.

## Acknowledgments

### FUNDING

The author's work is supported by a grant from the National Institute on Aging (R01AG067228).

## REFERENCES

1. Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA. Glial and neuronal control of brain blood flow. *Nature*. 2010;468:232–43. [PubMed: 21068832]
2. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. *Nature*. 2014;508:55–60. [PubMed: 24670647]
3. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci*. 2011;12:723–38. [PubMed: 22048062]
4. Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2019 Jul 2;73(25):3326–44. doi: 10.1016/j.jacc.2019.04.034 [PubMed: 31248555]
5. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. *Nutr Rev*. 2010;68(Suppl 2):S74–87. [PubMed: 21091952]

6. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat Rev Neurosci.* 2004;5:347–360. [PubMed: 15100718]
7. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. *Neuron.* 2010;67:181–98. [PubMed: 20670828]
8. Li B, Ohtomo R, Thunemann M, Adams SR, Yang J, Fu B, et al. Two-photon microscopic imaging of capillary red blood cell flux in mouse brain reveals vulnerability of cerebral white matter to hypoperfusion. *J Cereb Blood Flow Metab.* 2020 Mar;40(3):501–12. [PubMed: 30829101]
9. Wang L, Du Y, Wang K, Xu G, Luo S, He, G. Chronic cerebral hypoperfusion induces memory deficits and facilitates A $\beta$  generation in C57BL/6J mice. *Exp Neurol.* 2016;283:353–64. [PubMed: 27421879]
10. Hattori Y, Enmi J-I, Iguchi S, Saito S, Yamamoto Y, Tsuji M, et al. Gradual Carotid Artery Stenosis in Mice Closely Replicates Hypoperfusive Vascular Dementia in Humans. *J Am Heart Assoc.* 2016 Feb 22;5(2):e002757.
11. Jespersen SN, Østergaard L. The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism. *J Cereb Blood Flow Metab.* 2012;32:264–77. [PubMed: 22044867]
12. Rasmussen PM, Jespersen SN, Østergaard L. The Effects of Transit Time Heterogeneity on Brain Oxygenation during Rest and Functional Activation. *J. Cereb Blood Flow Metab.* 2015;35:432–42. [PubMed: 25492112]
13. Østergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, et al. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab.* 2016;36:302–25. [PubMed: 26661176]
14. Leal-Campanario R, Alarcon-Martinez L, Rieiro H, Martinez-Conde S, Alarcon-Martinez T, Zhao X, et al. Abnormal Capillary Vasodynamics Contribute to Ictal Neurodegeneration in Epilepsy. *Sci Rep.* 2017;7:43276. [PubMed: 28240297]
15. Ungvari Z, Tarantini S, Hertelendy P, Valcarcel-Ares MN, Fülöp GA, Logan S, et al. Cerebromicrovascular dysfunction predicts cognitive decline and gait abnormalities in a mouse model of whole brain irradiation-induced accelerated brain senescence. *GeroScience.* 2017;39:33–42. [PubMed: 28299642]
16. Ueno M, Chiba Y, Murakami R, Matsumoto K, Fujihara R, Uemura N, et al. Disturbance of Intracerebral Fluid Clearance and Blood–Brain Barrier in Vascular Cognitive Impairment. *Int J Mol Sci.* 2019 May;20(10):2600.
17. Regan RF, Guo Y. Toxic Effect of Hemoglobin on Spinal Cord Neurons in Culture. *J Neurotrauma.* 1998 Aug;15(8):645–53. [PubMed: 9726263]
18. Mhatre M, Nguyen A, Kashani S, Pham T, Adesina A, Grammas P. Thrombin, a mediator of neurotoxicity and memory impairment. *Neurobiol Aging.* 2004;25:783–93. [PubMed: 15165703]
19. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. *Neuron.* 2010;68:409–27. [PubMed: 21040844]
20. Komatani A, Yamaguchi K, Sugai Y, Takanashi T, Kera M, Shinohara M, et al. Assessment of demented patients by dynamic SPECT of inhaled xenon-133. *J. Nucl. Med* 1988;29:1621–6. [PubMed: 3262723]
21. Costa DC, Ell PJ, Burns A, Philpot M, Levy R. CBF Tomograms with [<sup>99m</sup>Tc-HMPAO in Patients with Dementia (Alzheimer Type and HIV) and Parkinson's Disease—Initial Results. *J Cereb Blood Flow Metab.* 1988;8:S109–15. [PubMed: 3263977]
22. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer's disease. *Neurobiol Aging.* 1992;13:483–91. [PubMed: 1508299]
23. O'Brien JT, Eagger S, Syed GM, Sahakian BJ, Levy R. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 1992;55:1182. [PubMed: 1479398]
24. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Demonstration of decreased posterior cingulate perfusion in mild Alzheimer's disease by means of H215O positron emission tomography. *Eur J Nucl Med.* 1997;24:670–3. [PubMed: 9169576]

25. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, et al. Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. *J Neurol Neurosurg Psychiatry*. 1999;66:228–32. [PubMed: 10071106]
26. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol*. 2001;64:575–611. [PubMed: 11311463]
27. Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. *Neuroimage*. 2005;28:1014–21. [PubMed: 16129627]
28. Vicenzini E, Ricciardi MC, Altieri M, Puccinelli F, Bonaffini N, Di Piero V, et al. Cerebrovascular Reactivity in Degenerative and Vascular Dementia: A Transcranial Doppler Study. *Eur Neurol*. 2007;58:84–89. [PubMed: 17565221]
29. Claassen JAHR, Diaz-Arrastia R, Martin-Cook K, Levine BD, Zhang R. Altered Cerebral Hemodynamics in Early Alzheimer Disease: A Pilot Study Using Transcranial Doppler. *J Alzheimers Dis*. 2009;17:621–9. [PubMed: 19433892]
30. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. *Radiology*. 2009;250:856–66. [PubMed: 19164119]
31. Ohnishi T, Hoshi H, Nagamachi S, Jinnouchi S, Flores LG, Futami S, et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. *J Nucl Med*. 1995;36:1163–9. [PubMed: 7790939]
32. Wolters FJ, Zonneveld HI, Hofman A, van der Lugt A, Koudstaal PJ, Vernooij MW. Cerebral Perfusion and the Risk of Dementia. *Circulation*. 2017;136:719–28. [PubMed: 28588075]
33. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in Cerebral Blood Flow and Glucose Utilization in Mice Overexpressing the Amyloid Precursor Protein. *Neurobiol Dis*. 2002;9:61–68. [PubMed: 11848685]
34. Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. *Mol Neurodegener*. 2014;9:28. [PubMed: 25108425]
35. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. *Brain Res Bull*. 1990;24:677–86. [PubMed: 2192775]
36. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. *Pharmacol Ther*. 1996;72:193–214. [PubMed: 9364575]
37. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer's disease. *Acta Neuropathol*. 2009;118:103–13. [PubMed: 19319544]
38. Farrall AJ, Wardlaw JM. Blood–brain barrier: Ageing and microvascular disease—systematic review and meta-analysis. *Neurobiol Aging*. 2009;30:33752.
39. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature*. 2012;485:512–6. [PubMed: 22622580]
40. Cruz Hernández JC, Bracko O, Kersbergen CJ, Muse V, Haft-Javaherian M, Berg M, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. *Nat Neurosci*. 2019;22:413–20. [PubMed: 30742116]
41. Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, Witter MP, Bierlaagh MA, et al. Functional MR imaging in Alzheimer's disease during memory encoding. *AJNR. Am J Neuroradiol*. 2000;21:1869–75. [PubMed: 11110539]
42. Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. *Neurology*. 2003;61:500–6. [PubMed: 12939424]
43. Hock C, Villringer K, Müller-Spahn F, Wenzel R, Heekeren H, Schuh-Hofer S, et al. Decrease in parietal cerebral hemoglobin oxygenation during performance of a verbal fluency task in patients with Alzheimer's disease monitored by means of near-infrared spectroscopy (NIRS)—correlation with simultaneous rCBF-PET measurements. *Brain Res*. 1997;755:293–303. [PubMed: 9175896]
44. Peters F, Collette F, Degueldre C, Sterpenich V, Majerus S, Salmon E. The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study. *Brain*. 2009;132:1833–46. [PubMed: 19433442]



45. Mentis MJ, Alexander GE, Krasuski J, Pietrini P, Furey ML, Schapiro MB. et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. *Am J Psychiatry*. 1998;155:785–94. [PubMed: 9619151]
46. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M. Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. *J Neurol*. 2006;253:58–64. [PubMed: 16096820]
47. Lee J, Wu W, Boas DA. Early capillary flux homogenization in response to neural activation. *J Cereb Blood Flow Metab*. 2015;36:375–80. [PubMed: 26661145]
48. Gutierrez-Jimenez E, Angleys H, Rasmussen PM, West MJ, Catalini L, Iversen NK, et al. Disturbances in the control of capillary flow in an aged APPswe/PS1 E9 model of Alzheimer's disease. *Neurobiol Aging*. 2018;62:82–94. [PubMed: 29131981]
49. Gold RT, Shao X, Sudduth TL, Jicha GA, Wilcock DM, Seago ER, et al. Water exchange rate across the blood-brain barrier is associated with CSF amyloid- $\beta$  42 in healthy older adults. *Alzheimers Dement*. 2021 Dec;17(12):2020–9. [PubMed: 33949773]
50. Montagne A, Nacion DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. *Nature*. 2020 May;581(7806):71–6. [PubMed: 32376954]
51. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Alzheimer's Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. *Nat Commun*. 2016 Jun 21;7:11934. [PubMed: 27327500]
52. Stefan S, Jonghwan Lee J. Deep learning toolbox for automated enhancement, segmentation, and graphing of cortical optical coherence tomography microangiograms. *Biomed Opt Express*. 2020 Nov 24;11(12):7325–42. [PubMed: 33409000]